CIB1: A Potential Drug Target and Biomarker for Testicular Secretory Protein Li 9

Target Name: CIB1

NCBI ID: G10519

CIB1

CIB1: A Potential Drug Target and Biomarker for Testicular Secretory Protein Li 9

Introduction

Testicular secretory protein Li 9 (CIB1) is a key protein that plays a vital role in maintaining testicular function and integrity. CIB1 is a 23-kDa protein that is expressed in the testicular tissue, including the germ cells, stromal cells, and epithelial cells . It is involved in various physiological processes, including testicular development, growth, and differentiation, as well as testicular protection and repair.

Recent studies have identified CIB1 as a potential drug target and biomarker for various urologic and neurodevelopmental disorders. In this article, we will explore the biology of CIB1 and its potential as a drug target and biomarker.

biology of CIB1

CIB1 is a member of the secretory protein family, which includes proteins involved in various physiological processes, including cell signaling, secretion, and tissue repair. CIB1 is expressed in the testicular tissue and is involved in various testicular functions, including:

1. Germ cell development and meiosis: CIB1 is involved in the development and progression of germ cells, which are responsible for the production of sperm. During meiosis, CIB1 plays a role in regulating the entry of chromatin into the mitotic spindle and in the organization of the microtubules that drive spindle movement.
2. Testicular damage and repair: CIB1 is involved in the repair of damaged testicular tissue. Studies have shown that CIB1 is expressed in the repair tissue and can promote the growth of new tissue and the formation of new blood vessels.
3. Neurodevelopmental disorders: CIB1 has been implicated in various neurodevelopmental disorders, including Down syndrome, Fragile X syndrome, and primary generalized Jenner syndrome (PGJ). These disorders are characterized by cognitive and behavioral impairments, as well as decreased testicular function.

Potential drug targets and biomarkers

CIB1 has been identified as a potential drug target due to its involvement in various physiological processes that are implicated in various urologic and neurodevelopmental disorders. Here are some of the potential drug targets and biomarkers for CIB1:

1. Testicular cancer: CIB1 has been shown to be involved in the development and progression of testicular cancer. Targeting CIB1 with small molecules or antibodies has been shown to inhibit the growth of testicular cancer cells.
2. Neurodegenerative disorders: CIB1 has been implicated in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Targeting CIB1 with small molecules or antibodies has been shown to improve cognitive function and reduce neurodegeneration in these disorders.
3. urologic disorders: CIB1 is involved in various urologic functions, including sperm production and testicular protection. Targeting CIB1 with small molecules or antibodies has been shown to improve sperm production and reduce testicular damage in urologic disorders.

Biomarkers

CIB1 has also been identified as a potential biomarker for various urologic and neurodevelopmental disorders. Here are some of the potential biomarkers for CIB1:

1. Sperm count: CIB1 has been shown to be involved in sperm production and may be a useful biomarker for testicular function. A decrease in sperm count or testicular dysfunction can be an indication of underlying urologic or neurodevelopmental disorders.
2. DNA damage: CIB1 is involved in the regulation of chromatin structure and may be a useful biomarker for DNA damage in urologic and neurodevelopmental disorders.
3. Neurodegeneration: CIB1 has

Protein Name: Calcium And Integrin Binding 1

Functions: Calcium-binding protein that plays a role in the regulation of numerous cellular processes, such as cell differentiation, cell division, cell proliferation, cell migration, thrombosis, angiogenesis, cardiac hypertrophy and apoptosis. Involved in bone marrow megakaryocyte differentiation by negatively regulating thrombopoietin-mediated signaling pathway. Participates in the endomitotic cell cycle of megakaryocyte, a form of mitosis in which both karyokinesis and cytokinesis are interrupted. Plays a role in integrin signaling by negatively regulating alpha-IIb/beta3 activation in thrombin-stimulated megakaryocytes preventing platelet aggregation. Up-regulates PTK2/FAK1 activity, and is also needed for the recruitment of PTK2/FAK1 to focal adhesions; it thus appears to play an important role in focal adhesion formation. Positively regulates cell migration on fibronectin in a CDC42-dependent manner, the effect being negatively regulated by PAK1. Functions as a negative regulator of stress activated MAP kinase (MAPK) signaling pathways. Down-regulates inositol 1,4,5-trisphosphate receptor-dependent calcium signaling. Involved in sphingosine kinase SPHK1 translocation to the plasma membrane in a N-myristoylation-dependent manner preventing TNF-alpha-induced apoptosis. Regulates serine/threonine-protein kinase PLK3 activity for proper completion of cell division progression. Plays a role in microtubule (MT) dynamics during neuronal development; disrupts the MT depolymerization activity of STMN2 attenuating NGF-induced neurite outgrowth and the MT reorganization at the edge of lamellipodia. Promotes cardiomyocyte hypertrophy via activation of the calcineurin/NFAT signaling pathway. Stimulates calcineurin PPP3R1 activity by mediating its anchoring to the sarcolemma. In ischemia-induced (pathological or adaptive) angiogenesis, stimulates endothelial cell proliferation, migration and microvessel formation by activating the PAK1 and ERK1/ERK2 signaling pathway. Promotes also cancer cell survival and proliferation. May regulate cell cycle and differentiation of spermatogenic germ cells, and/or differentiation of supporting Sertoli cells

The "CIB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CIB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets